Ground-breaking new research suggests that dramatically lower doses or shorter courses of revolutionary immunotherapy drugs could be highly effective. This finding may eventually pave the way for wider global access to life-saving cancer treatments. Lower-dose immunotherapy trials are showing promising potential. Drugs like Merck & Co’s Keytruda and Bristol Myers Squibb Co’s Opdivo have transformed oncology. They boost survival rates…
Tag: Opdivo
-
Immunotherapy for Cancer and Early-Stage Success
Ground-breaking advancements in immunotherapy are poised to transform cancer care. New data reveal the effectiveness of these immune-boosting drugs in treating a wider range of cancers at their earlier stages. Previously established as life-extending treatments for advanced diseases, drugs such as Bristol Myers Squibb’s Opdivo, AstraZeneca’s Imfinzi, and Roche’s Tecentriq are now demonstrating significant promise. They are preventing recurrence and…